Structure Therapeutics reported strong Phase IIb data for its oral GLP-1 candidate aleniglipron, showing up to 15% mean weight loss in a mid-stage study and sending investor interest higher. BioCentury and STAT coverage highlighted the efficacy numbers while noting tolerability and gastrointestinal side-effect rates remain a key question for regulatory and commercial prospects. Further market commentary compared Structure's small-molecule GLP-1 performance with peptide injectables from Novo Nordisk and Eli Lilly, emphasizing that tolerability and persistence of adverse events will shape differentiation. The company has ongoing dose-escalation cohorts and plans additional trials to define optimization and safety management.